133 related articles for article (PubMed ID: 38501689)
1. Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition.
Fluetsch A; Trunzer M; Gerebtzoff G; Rodríguez-Pérez R
Chem Res Toxicol; 2024 Apr; 37(4):549-560. PubMed ID: 38501689
[TBL] [Abstract][Full Text] [Related]
2. Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4.
Xu M; Lu Z; Wu Z; Gui M; Liu G; Tang Y; Li W
Mol Pharm; 2023 Jan; 20(1):194-205. PubMed ID: 36458739
[TBL] [Abstract][Full Text] [Related]
3. Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery.
Hu B; Zhou X; Mohutsky MA; Desai PV
Mol Pharm; 2020 Sep; 17(9):3600-3608. PubMed ID: 32794756
[TBL] [Abstract][Full Text] [Related]
4. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants.
Eng H; Tseng E; Cerny MA; Goosen TC; Obach RS
Drug Metab Dispos; 2020 Jun; 49(6):442-450. PubMed ID: 33811106
[TBL] [Abstract][Full Text] [Related]
6. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
Lutz JD; VandenBrink BM; Babu KN; Nelson WL; Kunze KL; Isoherranen N
Drug Metab Dispos; 2013 Dec; 41(12):2056-65. PubMed ID: 23785064
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
9. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
[TBL] [Abstract][Full Text] [Related]
10. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
12. High-throughput cytochrome P450 loss and metabolic intermediate complex assays to aid in designing out of CYP3A inactivation.
Russell DA; Cerny MA
Methods Enzymol; 2023; 690():341-368. PubMed ID: 37858534
[TBL] [Abstract][Full Text] [Related]
13. An Uncertainty-Guided Deep Learning Method Facilitates Rapid Screening of CYP3A4 Inhibitors.
Wang R; Liu Z; Gong J; Zhou Q; Guan X; Ge G
J Chem Inf Model; 2023 Dec; 63(24):7699-7710. PubMed ID: 38055780
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Kenny JR; Mukadam S; Zhang C; Tay S; Collins C; Galetin A; Khojasteh SC
Pharm Res; 2012 Jul; 29(7):1960-76. PubMed ID: 22415140
[TBL] [Abstract][Full Text] [Related]
15. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
[TBL] [Abstract][Full Text] [Related]
17. The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions.
Yan Z; Caldwell GW
Curr Top Med Chem; 2012; 12(11):1291-7. PubMed ID: 22571791
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
19. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms.
Kozakai K; Yamada Y; Oshikata M; Kawase T; Suzuki E; Haramaki Y; Taniguchi H
Drug Metab Pharmacokinet; 2014; 29(2):198-207. PubMed ID: 24172718
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]